HIV specialist Gilead beats financial forecasts

Gilead Sciences has announced its 2013 fourth-quarter and full-year financial results, with the last three months outperforming analysts’ predictions.

There was a 21 per cent rise in fourth-quarter earnings in 2013 versus the same period in 2012 – reaching 3.12 billion US dollars, and producing a net income for the period of 791.4 million US dollars.

“Full-year 2013 total revenues were $11.20 billion, up 15 per cent compared to $9.70 billion for 2012.

“Net income for 2013 was $3.07 billion, or $1.81 per diluted share, compared to $2.59 billion, or $1.64 per diluted share for 2012.”





Related news:

Gilead profit tops estimates on hepatitis C drug sales (Gilead).

Reference link:

Gilead Sciences announces fourth quarter and full year 2013 financial results (Gilead press release).

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.